Novo Nordisk has announced separate research collaborations with Omega Therapeutics and Cellarity.

The collaboration with Omega will exploit its proprietary technology platform to develop an epigenomic controller designed to enhance metabolic activity as part of a potential new therapeutic approach for the management of obesity.

The collaboration with Cellarity aims to discover new biological drivers of MASH and will leverage Cellarity's platform to develop a small-molecule therapy for this disease.

' It is essential that we complement our internal research with external innovation and work with partners who bring cutting-edge technology to the fore,' commented Marcus Schindler, Executive Vice President and Chief Scientific Officer at Novo Nordisk.


Copyright (c) 2024 CercleFinance.com. All rights reserved.